Abstract ES2-2: Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer

Abstract

Abstract Much as the development of molecularly based signatures (OncotypeDx®, MammaPrint®, ProSigna™, etc.) has revolutionized the decision-making process surrounding the need for adjuvant chemotherapy in women with early stage breast cancer, the development of prognostic and predictive signatures to determine the need and efficacy of radiation for women with breast cancer holds similar promise. While preliminary efforts to develop these signatures has been encouraging, much work remains in order to successfully translate these signatures into the clinic. In this educational session, we will review the current status of genomic-based signatures for radiation decision making. We will also review the barriers to clinical adoption and the molecularly stratified trials testing these signatures for treatment omission. Ultimately, for any of these tests to be translated into the clinic it will require demonstration of their accuracy and reproducibility as a test and perhaps more importantly, demonstration of clinical utility and an ability to improve outcomes for women with breast cancer. While not yet realized, the ongoing development of these signatures holds much promise as the field seeks to finally realize “personalized medicine” as it relates to radiation treatment for women with breast cancer. Citation Format: C Speers. Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr ES2-2.